

1 Title

2 Full Title: Enhancing Genetic Association Power in Endometriosis through Unsupervised Clustering
3 of Clinical Subtypes Identified from Electronic Health Records

4 Short Title: The genetics of clinical endometriosis subtypes

5 Authors

6 Lindsay Guare¹, Leigh Ann Humphrey², Margaret Rush², Meredith Pollie², Yuan Luo³, Chunhua
7 Weng⁴, Wei-Qi Wei⁵, Leah Kottyan⁶, Gail Jarvik⁷, Noemie Elhadad⁴, Penn Medicine Biobank,
8 Regeneron Genetics Center, Krina Zondervan⁸, Stacey Missmer⁹, Marijana Vujkovic¹⁰, Digna Velez-
9 Edwards⁵, Suneeta Senapati², Shefali Setia-Verma^{11*}

10 *Corresponding Author: Shefali Setia-Verma (shefali.setiaverma@pennmedicine.upenn.edu)

11 Affiliations

12 1. Genomics and Computational Biology, University of Pennsylvania

13 2. Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania

14 3. Northwestern University

15 4. Columbia University

16 5. Vanderbilt University Medical Center

17 6. Cincinnati Children's Hospital Medical Center

18 7. University of Washington

19 8. University of Oxford

20 9. Michigan State University

21 10. University of Pennsylvania

22 11. Department of Pathology and Laboratory Medicine, University of Pennsylvania

23 Abstract

24 **Background:** Endometriosis affects 10% of reproductive-age women, and yet, it goes undiagnosed
25 for 3.6 years on average after symptoms onset. Despite large GWAS meta-analyses ($N > 750,000$),
26 only a few dozen causal loci have been identified. We hypothesized that the challenges in
27 identifying causal genes for endometriosis stem from heterogeneity across clinical and biological
28 factors underlying endometriosis diagnosis.

29 **Methods:** We extracted known endometriosis risk factors, symptoms, and concomitant conditions
30 from the Penn Medicine Biobank (PMBB) and performed unsupervised spectral clustering on 4,078
31 women with endometriosis. The 5 clusters were characterized by utilizing additional electronic
32 health record (EHR) variables, such as endometriosis-related comorbidities and confirmed surgical
33 phenotypes. From four EHR-linked genetic datasets, PMBB, eMERGE, AOU, and UKBB, we extracted
34 lead variants and tag variants 39 known endometriosis loci for association testing. We meta-
35 analyzed ancestry-stratified case/control tests for each locus and cluster in addition to a positive
36 control (Total $N_{\text{endometriosis cases}} = 10,108$).

37 **Results:** We have designated the five subtype clusters as pain comorbidities, uterine disorders,
38 pregnancy complications, cardiometabolic comorbidities, and EHR-asymptomatic based on
39 enriched features from each group. One locus, *RNLS*, surpassed the genome-wide significant
40 threshold in the positive control. Thirteen more loci reached a Bonferroni threshold of 1.3×10^{-3}
41 ($0.05 / 39$) in the positive control. The cluster-stratified tests yielded more significant associations
42 than the positive control for anywhere from 5 to 15 loci depending on the cluster. Bonferroni
43 significant loci were identified for four out of five clusters, including *WNT4* and *GREB1* for the
44 uterine disorders cluster, *RNLS* for the cardiometabolic cluster, *FSHB* for the pregnancy
45 complications cluster, and *SYNE1* and *CDKN2B-AS1* for the EHR-asymptomatic cluster. This study
46 enhances our understanding of the clinical presentation patterns of endometriosis subtypes,
47 showcasing the innovative approach employed to investigate this complex disease.

48 Abbreviations

49	AOU	All of Us Biobank
50	eMERGE	electronic medical record and genomics network
51	EHR	electronic health record
52	GWAS	genome-wide association study
53	ICD	international classification of diseases
54	PMBB	Penn Medicine biobank
55	UKBB	United Kingdom biobank

56 Introduction

57 Endometriosis, a complex gynecological condition affects 10% of women of reproductive
58 age globally and more than 50% of women with infertility (1), yet it often goes either undiagnosed
59 or misdiagnosed, leading to delayed diagnoses and delivery of effective therapy (2,3).
60 Endometriosis is primarily characterized by the presence of endometrial-like tissue outside of the
61 uterus. For managing the condition without surgery, the main treatments include pain relief and
62 hormone-based therapies, neither of which are curative. A notable number of women with
63 endometriosis receive opioids for pain management, despite the need for more sustainable and
64 effective treatment options (4,5). On the other hand, hormonal therapies may have limitations to
65 utilization due to severe side effects or a desire to become pregnant. Typically, the treatment for
66 endometriosis often includes both medical and surgical approaches, however 30-50% of patients
67 with severe endometriosis may require a second surgery within 3-5 years (6). The most
68 comprehensive surgical management involves a hysterectomy with bilateral salpingoophorectomy
69 (7). Treatment and health care visits accumulate many direct and indirect costs for women with
70 endometriosis. The estimated economic cost of endometriosis in the US is ~\$10k per patient which
71 is ~14% higher than that of diabetes (8), and does not include the costs patients incur by having to

72 miss work days because of their symptoms. In total, endometriosis presents a high economic
73 burden that exceeds \$22 billion in the U.S. alone (9). The condition not only imposes significant
74 costs but also involves severe symptoms, delayed diagnosis, limited treatment options, and
75 financial strain: challenges that could be significantly mitigated with a more detailed
76 understanding of the disease.

77 Electronic Health Records (EHRs) represent a rich, yet underutilized, data source for
78 capturing the phenotypic spectrum of endometriosis (10). Although the symptoms for
79 endometriosis can be quite severe, including chronic debilitating pain, dyspareunia, and infertility,
80 the average time to diagnosis is 4.5 years (11), in part because the only way to definitively diagnose
81 endometriosis is by surgical observation of endometrial lesions growing outside of the uterus (e.g.
82 abdominal cavity, pelvis, ovaries, etc.) (12). The variability in symptoms and disease presentation
83 adds to the difficulty of diagnosis and hinders the optimal use of electronic health records (EHRs) in
84 research for accurately identifying affected individuals and control subjects (13–15), which is
85 critical for understanding the disease and advancing treatment strategies. The depth and breadth of
86 EHR data provide a unique opportunity to apply unsupervised learning techniques for the
87 identification of distinct phenotypic clusters that may correspond to clinical subtypes of
88 endometriosis. Such an approach aligns with precision medicine's goal to tailor diagnosis and
89 treatment strategies to individual patient characteristics, potentially revealing novel insights into
90 the disease's pathophysiology.

91 Better understanding of the disease mechanisms of endometriosis could lead to improved
92 diagnostic practices, reducing costs to the healthcare system and improving quality of life through
93 treatment and earlier diagnosis for patients. In spite of the prevalence and severity of
94 endometriosis, etiology of endometriosis is still poorly understood. The pursuit thus far of
95 biomarkers and drug targets based on genetic contributions of disease in patients with
96 endometriosis has mainly included genome-wide association studies to identify genetic variants

97 contributing to the disease (16,17). Twin studies have estimated the heritability of endometriosis to
98 be 47.5% (18), and common variants are estimated to contributed 26% of phenotypic variance
99 (19), but the largest GWAS to-date ($N > 750,000$, 60,674 cases) has only explained 9% of the
100 phenotypic variance (17). Although these recent advances in genomic studies have promised
101 insights into the underlying genetic mechanisms of endometriosis, yet the heterogeneity of the
102 disease presentation has consistently complicated these efforts. Traditional genetic association
103 studies have struggled to untangle the intricate web of genotypic and phenotypic diversity within
104 endometriosis patients, leading to a critical need for innovative approaches to dissect the disease's
105 complexity.

106 We hypothesized that underlying clinical heterogeneity is obscuring the genetic
107 mechanisms and preventing large-scale genetic studies from explaining more of the heritability.
108 Endometriosis causes a wide range of symptoms and concomitant conditions, including severe
109 chronic pain, gastrointestinal inflammation, and infertility. Additionally, many symptoms of
110 endometriosis are shared between other gynecological diseases such as primary dysmenorrhea,
111 ovarian cysts, and pelvic inflammatory disease; making symptom-based diagnosis challenging
112 (20,21). Recent studies have highlighted the importance of complex disease subtyping in improving
113 our understanding of the genetic mechanisms underlying endometriosis. For example, a recent
114 study on polycystic ovary syndrome (PCOS) used unsupervised clustering to identify three
115 subtypes of PCOS based on lab and biometric values before conducting genome-wide association
116 study for each subtype (22). This approach allowed for a more nuanced understanding of the
117 genetic basis of PCOS and could be applied to endometriosis to identify subtypes with distinct
118 genetic mechanisms. Building on the premise that a more nuanced understanding of endometriosis
119 subtypes could unlock new genetic associations, our study leverages unsupervised, phenotypic
120 clustering analysis of EHR data to systematically identify and characterize clinical subtypes of
121 endometriosis. By dissecting the heterogeneity inherent in the disease, we aim to increase the

122 power of genetic association analyses, facilitating the identification of subtype-specific disease
123 mechanisms. This approach not only promises to enhance our understanding of endometriosis
124 genetics but also to refine diagnostic criteria and inform more targeted and effective treatment
125 strategies.

126 In conclusion, the complex nature of endometriosis, with its diverse symptoms and
127 overlapping features with other gynecological diseases, presents challenges for understanding its
128 genetic mechanisms. In this manuscript, we detail the methodology and findings of our study, which
129 integrates unsupervised phenotypic clustering with subsequent genetic association analyses for
130 each identified endometriosis subtype. By doing so, we aim to bridge the gap between clinical
131 observations and genetic research in endometriosis, providing a roadmap for future studies to
132 explore the genetic underpinnings of this complex disease with renewed clarity and precision. This
133 deeper understanding may pave the way for more targeted and personalized approaches to
134 diagnosis, treatment, and management of this debilitating condition. Further research and large-
135 scale genetic studies are needed to fully elucidate the genetic architecture of endometriosis and its
136 subtypes, ultimately leading to improved outcomes for affected individuals.

137 **Methods**

138 **Datasets Used for Sub-phenotyping and Genetic Association**

139 The Penn Medicine Biobank (PMBB) is the University of Pennsylvania's health system-
140 based biobank which consists of about 250,000 consented participants, with 43,624 of those having
141 imputed genotype data (imputed to TOPMED reference panel) linked with their electronic health
142 record (EHR) history. The PMBB is an electronic health record (EHR)-linked biobank that integrates
143 a wide variety of health-related information, including diagnosis codes, laboratory measurements,
144 imaging data, and lifestyle information, with genomic and biomarker data. The PMBB is one of the

145 most diverse medical biobanks, with approximately 30% of participants being of non-European
146 ancestry. This diversity is crucial for ensuring that research findings are applicable to a broad range
147 of populations. The biobank also benefits from a median of seven years of longitudinal data in the
148 EHR, providing valuable information on participants' health histories (22). For our study, we
149 treated the PMBB as two distinct datasets: those without and those with genotype data. EHR data
150 from the non-genotyped PMBB were used for cluster derivation whereas the genotyped PMBB
151 cohort was used in the genetic analyses.

152 The Electronic Medical Records and Genomics (eMERGE) network is a National Human
153 Genome Research Institute-funded consortium engaged in the development of methods and best
154 practices for using the electronic medical record as a tool for genomic research. The eMERGE
155 network is a publicly-available dataset with contributions from multiple health systems within the
156 United States which contains about 100,000 participants with linked health records and imputed
157 genomic data (imputed to HRC reference panel) (23). The eMERGE consortium validated the
158 hypothesis that clinical data derived from electronic medical records can be used successfully for
159 complex genomic analysis of disease susceptibility across diverse patient populations (24). The
160 eMERGE network has shown the efficiency that can result from the use of electronic health record
161 data.

162 The All of Us (AOU) Research Program is an initiative created by the NIH to recruit
163 demographically diverse individuals to the largest US-based biobank to-date. Recruitment began in
164 2018, and since then, over 400,000 people have signed up and submitted baseline questions (25).
165 245,388 of them have short-read whole genome sequence data, collectively representing over one
166 billion genetic variants (26). Participants' EHRs are contributed to the AOU data processing center
167 using the Sync for Science platform (27), which works with EHR vendors such as Epic and Cerner to
168 collate structured patient data for research use (28).

169 The UK Biobank (UKBB) is a large and comprehensive dataset that provides valuable
170 resources for researchers studying a wide range of health-related topics. The UKBB is a population-
171 based publicly available dataset consisting of about 500,000 UK citizens with EHR data, health
172 survey data, and imputed genotypes. The UK Biobank has performed genome-wide genotyping on
173 all participants using the UK Biobank Axiom Array (29). This array directly measures
174 approximately 850,000 variants, and more than 90 million variants are imputed using the
175 Haplotype Reference Consortium and UK10K + 1000 Genomes reference panels.

176 All four of the biobanks mentioned above (PMBB, eMERGE, AOU, and UKBB) utilize the
177 Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) to represent
178 structured EHR data in a harmonized format (30). For this study, we utilized women with ICD-
179 diagnosed endometriosis in the non-genotyped PMBB cohort ($N_{\text{endo}} = 4,078$) as the derivation
180 dataset for the clinical subtypes. For deeper characterization of our subtypes, we performed chart-
181 reviews on 682 randomly selected endometriosis cases from the genotyped PMBB. Then, we meta-
182 analyzed women from the genotyped PMBB ($N = 20,697$, $N_{\text{endo}} = 1,198$), six non-pediatric sites
183 within the eMERGE network ($N = 51,800$, $N_{\text{endo}} = 2,243$), the AOU research program ($N = 108,098$,
184 $N_{\text{endo}} = 2,126$), and UKBB ($N = 261,824$, $N_{\text{endo}} = 4,451$) to form our main genetic analysis test set ($N =$
185 $442,419$, $N_{\text{endo}} = 10,018$).

186 Each of the biobanks projected their samples onto the thousand genomes reference
187 population and performed clustering to assign genetically inferred ancestry labels corresponding to
188 those from the thousand genomes project (31). We restricted our genetic association analyses to
189 the groups which had substantial sample sizes, which were those with high similarity the AFR and
190 EUR thousand genomes superpopulations. We will refer to those groups using AFR and EUR from
191 here on out.

192 Extraction of Endometriosis-Related Clinical Features

193 Patients with endometriosis have heterogeneous clinical presentations; there are a wide
194 variety of associated symptoms, risk factors, and comorbidities. We first determined participants'
195 case-control status of endometriosis using structured EHR data: ICD-9 and ICD-10 billing codes 617
196 and N80, respectively. Then for endometriosis cases, we determined whether each individual had a
197 history of endometriosis-related clinical features. In total, we extracted 39 ICD-based features
198 (Table S1): 9 ICD-based anatomical subtypes, 14 comorbidities, 8 symptoms, and 8 pregnancy-
199 related phenotypes. We selected only symptoms, comorbidities, and pregnancy-related conditions
200 for clustering, removing the 9 anatomical subtypes to be used downstream in cluster
201 characterization. We further restricted these conditions to those with a prevalence amongst
202 endometriosis cases in the subtype dataset of at least 5%, leaving us with 17 features for the
203 clustering analysis (Figure S1).

204 Unsupervised Clustering

205 We tested four popular methods for unsupervised clustering: spectral clustering, density-
206 based spatial clustering of applications with noise (DBSCAN), hierarchical agglomerative clustering,
207 and k-means clustering. Spectral clustering identifies clusters by decomposing a dataset's affinity
208 matrix into its eigenvectors and then clustering in the eigenvector space using QR clustering
209 algorithm (32,33). DBSCAN is an algorithm which identifies dense regions of data points to discover
210 clusters (34). Hierarchical agglomerative clustering is an unsupervised classification method that
211 uses a pairwise distance matrix to iteratively merge nearby points together (35). K-means
212 clustering randomly initializes centroids for each cluster and then alternates between assigning
213 data points to their nearest centroid and adjusting the centroids until convergence (36).

214 In addition to choosing an algorithm, a common struggle with unsupervised clustering is
215 choosing a target number of clusters in a non-arbitrary way. We used several empirical metrics for

216 this: silhouette score, distortion score, and a metric we developed to represent the “evenness” of
217 clusters. The silhouette score is a metric which considers both intra- and inter-cluster distances to
218 assess tightness within a cluster and distance between clusters; higher silhouette scores indicate
219 better quality clusters. The distortion score is the sum of squared errors with respect to the
220 centroid of each cluster, thus it is desired to minimize distortion. Our evenness metric, optimized by
221 minimization, was defined as the fractional difference between the size of the largest and smallest
222 clusters. We measured these metrics across tests for 2-20 clusters for each of the four clustering
223 methods (except for DBSCAN which automatically infers the optimal number of clusters).

224 Characterization of Unsupervised Clusters

225 After identifying clinical clusters within our observation dataset, our objective was to
226 delineate their characteristics. We performed two-population z-score proportion tests (37) to
227 determine if the rates of input conditions were significantly different on a cluster-vs-other-clusters
228 basis. For our training set (the non-genotyped PMBB, $N_{\text{endo}} = 4,078$), we examined two sets of
229 features for the z-score tests: the 17 input features as well as ICD-based anatomical subtypes of
230 endometriosis including adenomyosis, endometrioma, superficial lesions, and deep lesions
231 (Supplementary Table S2). For characterizing our clusters, we also utilized a chart-reviewed
232 dataset of 682 genotyped PMBB patients with endometriosis ICD codes. The features considered
233 here were confirmed endometriosis and adenomyosis status and chart-abstracted symptoms,
234 comorbidities, and surgical phenotypes (Supplementary Table S3). By considering the cluster-
235 specific differences in these EHR-derived features among the two datasets, we could observe
236 patterns in clinical presentation. Based on these patterns, we assigned labels to each cluster.

237 Cluster-Stratified Candidate Gene Association Testing

238 To identify genetic heterogeneity among the varied clinical presentations of endometriosis,
239 we performed cluster-stratified, ancestry-stratified candidate gene association studies. Using PLINK

240 2.0 (38), we extracted single nucleotide polymorphisms (SNPs) in LD (kb distance < 0.5 Mb and $R^2 >$
241 0.1) with 39 autosomal lead SNPs reported in the most recent endometriosis GWAS(17). LD was
242 computed based on the thousand genomes reference panel (31). Cluster phenotypes were assigned
243 for PMBB, eMERGE, and AOU using a K-Nearest neighbors' classifier (39) with K=3 on the same 17
244 ICD-based features. For each study, we employed a linear mixed model regression method
245 employed in SAIGE (40) to test for associations between genotypes and case-control status. Cases
246 were females with endometriosis from one cluster and controls were biological females with no ICD
247 history of endometriosis. In the regression models we included the first four principal components,
248 age, and batch indicators (eMERGE only) as covariates. The ancestry-stratified results of these
249 studies were then meta-analyzed using Plink 1.9 (41) for each of the cluster-phenotypes. We also
250 tested a baseline overall endometriosis (cases from all clusters combined) as a positive control to
251 identify how many known loci we were able to replicate. Because multiple genetic ancestry groups
252 were included, we chose a random-effects meta-analysis, which is more robust to heterogeneity
253 (42).

254 Results

255 Derivation, Study, and Validation Datasets

256 This study utilized five datasets to investigate the genetic mechanisms underlying
257 endometriosis and its subtypes. The datasets used were endometriosis cases in the non-genotyped
258 PMBB for the derivation of clusters, a chart-reviewed endometriosis cohort to help characterize the
259 clusters, the genotyped PMBB, six sites within the eMERGE network, AOU, and UKBB for genome-
260 wide association analyses (See Methods). The sample sizes for each cohort, the mean age at
261 diagnosis, the number of cases and controls, and the mean age at the time of data pull for each
262 cohort are shown in Table 1. See Methods for details on each of the four datasets. By leveraging

263 these datasets, the study aimed to identify endometriosis subtypes and gain insights into the
264 genetic factors associated with endometriosis and its subtypes.

265


266

267 **Table 1:** Cohort sample size and average age of cases and controls for the datasets used in this
 268 analysis. Age was considered the age as of when the EHR data were collected.

Dataset	Endometriosis	N (AFR / EUR)	Mean Age (SD)
Cluster Derivation Set:			
Non-Genotyped PMBB	Cases	4,078 (NA)	49.9 (13.3)
Genetic Association Sets:			
AOU	Cases	2,126 (542 / 1,584)	52.2 (12.8)
	Controls	108,099 (31,435 / 76,664)	56.8 (16.8)
eMERGE	Cases	2,243 (353 / 1,890)	59.9 (14.6)
	Controls	49,557 (9,934 / 39,623)	59.7 (23.4)
PMBB	Cases	1,198 (562 / 636)	54.2 (12.9)
	Controls	19,493 (6,524 / 12,969)	60.0 (17.8)
UKBB	Cases	4,541 (112 / 4,429)	51.5 (7.5)
	Controls	257,283 (4,524 / 252,759)	56.6 (8.0)
Meta-Analysis Totals:			
META	Cases	10,108 (1,569 / 8,539)	53.9 (11.3)
	Controls	434,432 (52,417 / 382,015)	57.1 (13.6)

269 Derivation of Unsupervised of Clusters


270 Unsupervised clustering was performed in non-genotyped PMBB dataset of 4,078 women
 271 with EHR-diagnosed endometriosis using 17 clinical features (supplementary figure S2). We tested
 272 four methods for unsupervised clustering as well as 19 values for the number of clusters (K=2-20)
 273 and measured three metrics to empirically choose a clustering method and number of clusters
 274 (Figure 1).



275
 276 **Figure 1:** testing various clustering algorithms and K-values to empirically choose an optimal
 277 method. The three metrics shown are (a) Manhattan-distance-based silhouette score, (b) distortion

278 or sum of squared errors, and (c) evenness represented by the difference in fraction between the
279 largest and smallest clusters. Based on these tests, we chose spectral clustering with K=5.

280
281 Based on these tests, we first eliminated DBSCAN because the inferred number of clusters
282 was 131, a far too complex model to be useful or interpretable. Next, we eliminated hierarchical
283 clustering because the sizes of the resulting clusters were more uneven than the other methods.
284 Spectral clustering and k-means clustering were ultimately more difficult to choose between, but
285 when we focused on the shapes of the distortion curves across the values of K, we observed that k-
286 means lacked an “elbow” to show a clear optimal K value whereas spectral clustering clearly
287 indicated 5 as an ideal K with a local minimum. Thus, we chose spectral clustering with K=5 as our
288 unsupervised subtyping model. The sizes of the final clusters were: (1) 441 - 11%, (2) 686 - 17%,
289 (3) 1,151- 28%, (4) 796 - 20%, and (5) 1,004 - 25%. Figure 2 illustrates the eigenvectors of the
290 affinity matrix which were used for clustering the data points.




291
292 **Figure 2:** pairwise scatter plots of the first five eigenvectors of the affinity matrix used for spectral
293 clustering, colored by cluster. This five-dimensional eigenvector space was used for clustering. The
294 diagonal shows kernel density estimator plots for each of the five eigenvectors.

295
296

297 Data-Driven Cluster Characterization

298 After clustering, we aimed to characterize these clusters by observing patterns in clinical
 299 presentation (prevalence) amongst the input features. We performed two sets of z-score
 300 proportion tests comparing prevalence of each feature between each cluster and the other four
 301 clusters in our training set. The first set of tests was performed on the original cluster derivation
 302 cohort, and the features included were the 17 input features (symptoms and comorbidities with
 303 prevalence > 5%) as well as ICD-defined anatomical subtypes of endometriosis (Figure 3).




304
 305 **Figure 3:** feature tests for the non-genotyped PMBB training set. Shown are (a) z-scores for the
 306 difference in proportion tests, annotated with p-values that are significant and (b) feature
 307 prevalence by cluster to provide context for the z-score tests.

308
 309 Among the five clusters identified in the training set, there were many input features and
 310 ICD-based anatomical subtypes with significantly different proportions. To identify distinguishing

311 features between the clusters, we focus on phenotypes which were significantly enriched and had
312 the highest prevalence in that cluster. Cluster one had the highest rates of (and was significantly
313 enriched for) dysuria (Z=8.9), migraine (Z=10.6), IBS (Z=10.3), fibromyalgia (Z=15.3), asthma
314 (10.3), abdominal pelvic pain (Z=13.6), and shortness of breath (Z=13.5). Cluster two had the
315 highest rates of the following significantly enriched traits: dysmenorrhea (Z=21.9), infertility
316 (Z=5.9), irregular menstruation (Z=31.75), leiomyoma of uterus (Z=21.9), and uterine
317 endometriosis defined by ICD-9 617.0* or ICD-10 N80.0* (Z=13.4). Cluster three's defining features
318 were high risk pregnancy supervision (Z=7.1), superficial lesions defined by ICD-9 617.3* or ICD-10
319 N80.3* (Z=7.1), and lower abdominal pain (Z=14.6). Individuals in cluster four had highest
320 prevalence of abnormal cholesterol (Z=33.1) and hypertension (Z=33.9), while cluster five was only
321 enriched for unspecified endometriosis defined as ICD-9 617.9* or ICD-10 N80.9* (Z=7.0).

322 The second set of tests was performed on a subset of endometriosis cases (N=682) from the
323 genotyped PMBB for whom chart reviews were performed by OB-GYN clinical fellows at the
324 University of Pennsylvania Hospital System. The features tested were gold standard confirmed
325 diagnoses (endometriosis, adenomyosis, fibroids, and any ICD false positives), surgical subtypes,
326 hormone use at the time of confirmation procedure, and symptoms identified from a combination
327 of structured data and notes (Figure 4).



328
 329 **Figure 4:** feature tests for the chart reviewed PMBB dataset. Shown are (a) z-scores for the
 330 difference in proportion tests, annotated with p-values that are significant and (b) feature
 331 prevalence by cluster to provide context for the z-score tests.
 332 Because the size of our chart-reviewed dataset was limited, there were fewer significant
 333 tests. For cluster one, the phenotypes which were most significantly prevalent were interstitial
 334 cystitis ($Z=3.8$) and fibromyalgia ($Z=6.9$). For cluster two, the defining features were confirmed
 335 adenomyosis status ($Z=3.7$), confirmed uterine fibroids ($Z=7.1$), and symptomatic bleeding ($Z=5.3$).
 336 Cluster three's most highly enriched features were pelvic pain ($Z=3.5$) and hormone use at the time
 337 of surgery ($Z=4.1$). Considering the enriched features for each cluster among the two sets of tests,
 338 we defined the following labels for 5 clusters: (1) pain comorbidities, (2) uterine disorders, (3)
 339 pregnancy complications, (4) cardiometabolic comorbidities, and (5) EHR-asymptomatic.

340 Candidate Gene Association Testing Stratified by Phenotypic Cluster


341 We applied the subtype classifications observed in our derivation set to our four genetic
 342 association datasets, PMBB, eMERGE, AOU, and UKBB. We used a K-nearest neighbors model with
 343 the same 17 EHR-derived features to assign endometriosis cases to the five phenotypes (Table 2).

344 **Table 2:** counts and proportions of endometriosis cases in each cluster by dataset.

Dataset	Pain Comorbidities	Uterine Disorders	Pregnancy Complications	Cardiometabolic Comorbidities	EHR-Asymptomatic
Cluster Derivation Set:					
Training	441 (10.8%)	686 (16.8%)	1,151 (28.2%)	796 (19.5%)	1,004 (24.6%)
Genetic Association Sets:					
AOU	713 (21.8%)	690 (21.1%)	723 (22.1%)	783 (23.9%)	362 (11.1%)
eMERGE	495 (22.1%)	505 (22.5%)	382 (17.0%)	709 (31.6%)	152 (6.8%)
PMBB	200 (16.7%)	222 (18.5%)	273 (22.8%)	366 (30.6%)	137 (11.4%)
UKBB	231 (5.1%)	607 (13.4%)	842 (18.5%)	285 (6.3%)	2,576 (56.7%)
Meta-Analysis Totals:					
META	1,639 (14.6%)	2,024 (18.0%)	2,220 (19.7%)	2,143 (19.0%)	3,227 (28.7%)

345
 346 The smallest cluster was the pain comorbidities cluster, with only 14.6% of total
 347 endometriosis cases being assigned to this cluster. The EHR-asymptomatic cluster was the largest
 348 cluster overall. The other three clusters occurred in relatively even proportions in the overall
 349 meta-analysis group at 18.0% (uterine disorders), 19.7% (pregnancy complications), and 19.0%
 350 (cardiometabolic comorbidities).

351 To establish a reference for the expected level of signal replication, we began with a positive
 352 control test. We conducted association tests on 39 established genetic locations (autosomes only)
 353 known to be linked to endometriosis. (Figure 5).



354

355 **Figure 5:** results for our endometriosis case vs control positive control association tests at each of
 356 the 39 known loci. Shown are the lead SNPs from the Rahmioglu et al 2023 GWAS as well their tag
 357 SNPs in LD (kb distance < 0.5 Mb and $R^2 > 0.1$). X-axis labels are from the known GWAS.


358

359 Our positive control test resulted in fourteen replicating loci. Only one was genome-wide
 360 significant, *RNLS/10q23.31* ($P = 1.91 \times 10^{-9}$, rs792212:T). Thirteen were significant at a Bon Ferroni-
 361 corrected threshold of 0.05 / 39: *WNT4/1p36.12* ($P = 9.12 \times 10^{-8}$, rs2235529:T), *DNM3/1q24.3* ($P =$
 362 3.54×10^{-5} , rs655853:C), *GREB1/2p25.1* ($P = 6.55 \times 10^{-4}$, rs34532804:A), *PDLIM5/4q22.3* ($P = 8.58 \times 10^{-$
 363 4 , rs1493112:T), *EBF1/5q33.3* ($P = 7.64 \times 10^{-4}$, rs1878936:C), *SYNE1/6q25.1* ($P = 3.20 \times 10^{-4}$,
 364 rs13206045:C), *GDAP1/8q21.11* ($P = 4.19 \times 10^{-7}$, rs10957712:T), *CDKN2B-AS1/9p21.3* ($P = 1.75 \times 10^{-6}$,
 365 rs10122243:T), *ASTN2/9q33.1* ($P = 9.01 \times 10^{-4}$, rs62576127:A), *ABO/9q34.2* ($P = 5.87 \times 10^{-4}$,
 366 rs495828:G), *FSHB/11p14.1* ($P = 1.17 \times 10^{-3}$, rs11031006:A), *WT1/11p14.1* ($P = 2.85 \times 10^{-4}$,
 367 rs72638188:T), *DLEU1/13q14.2* ($P = 2.24 \times 10^{-4}$, rs9568417:G).

368

369 To test whether stratifying by clinical presentation allowed for greater resolution in genetic
 370 associations, we performed case-control candidate gene association studies for the five phenotypic
 371 clusters by meta-analyzing ancestry-stratified summary statistics from four EHR-linked genetic
 372 datasets: PMBB, eMERGE, AOU, and UKBB. We observe 18 / 39 loci (46%) significantly associating
 with one or more clusters (Figure 6a, 6b). Also, for up to 15 loci, the cluster-stratified phenotypes

373 yield stronger associations than the positive control despite having smaller sample sizes (Figure
374 6c).



375
376 **Figure 6:** Phenotype-specific association test results. The top panel (a) indicates which known loci
377 were significantly replicated by the positive control and five clusters. The bottom left panel (b)
378 shows the number and names of statistically significant associations for each phenotype. The
379 bottom right panel (c) shows the number of loci for which each phenotype had a more significant
380 association than the baseline.

381 The smallest cluster, cluster one, with high rates of pain comorbidities, was not significantly
382 associated with any known loci, but it was more significantly associated than the positive control
383 for eight loci as shown in Figure 6c. The uterine disorders cluster (two) was significantly associated
384 with four loci, *WNT4/1p36.12*, *DNM3/1q24.3*, *GREB1/2p25.1*, and *GDAP1/8q21.11*. Out of the seven

385 loci significantly associated with the pregnancy complications cluster (three), three of them were
386 not significantly associated with any other clusters or the positive control: *KDR/4q12*, *7p15.2*, and
387 *KCTD9/8p21.2*. Cluster four, enriched for cardiometabolic comorbidities, was significantly
388 associated with one locus, *RNLS/10q23.31*, the strongest hit from the positive control. *RNLS* was
389 also significantly associated with clusters three and five. Eleven loci were significantly associated
390 with the EHR-asymptomatic cluster, and six of those (*BSN/3p21.31*, *ID4/6p22.3*, *CD109/6q13*,
391 *MLLT10/10p12.31*, *IGF1/12q23.2*, and *SKAP1/17q21.32*) had no other associations, even with the
392 positive control.

393 Discussion

394 Endometriosis presents with heterogeneous symptoms ranging from severe pain to
395 infertility, contributing to varying patient experiences and treatment responses. Several large
396 genome-wide association studies and meta-analyses have been performed for endometriosis to-
397 date. However, the genomic underpinnings of endometriosis remain incompletely understood,
398 largely due to the clinical heterogeneity and the limitations of traditional genome-wide association
399 studies (GWAS) that aggregate all cases into a single analysis pool. This approach may obscure
400 genetic variations specific to different endometriosis phenotypes, thus necessitating more refined
401 stratification techniques. There are various approaches to phenotyping participants for these
402 studies including surgical notes and electronic health records. While there have also been analyses
403 which account for disease progression (17), there have not been any genome-wide investigations
404 into the genetics underlying the heterogeneous presentation patterns of endometriosis.

405 In this study, we aimed to investigate the genetics of heterogeneity in endometriosis by
406 defining data-driven subtypes in women from the non-genotyped PMBB endometriosis population
407 (N=4,078). We extracted clinical features known to be associated with endometriosis and
408 performed unsupervised spectral clustering, identifying five clusters. Unsupervised clustering was

409 an ideal approach for this study because it a way to find patterns in the data without introducing
410 prior knowledge or bias. We chose spectral clustering with five clusters based on empirical metrics
411 measured by comparing four different unsupervised clustering methods across a range of K values
412 (2-20 clusters). This method had the best tradeoff between squared error, silhouette score, and
413 cluster evenness.

414 To understand the clinical presentation patterns of each of the clusters, we compared the
415 rates of the input features, diagnoses, and chart-reviewed phenotypes amongst them. Based on
416 statistical enrichment testing across the features, the clusters were labeled as (1) pain
417 comorbidities, (2) uterine disorders, (3) pregnancy complications, (4) cardiometabolic
418 comorbidities, and (5) EHR-asymptomatic. This nuanced phenotyping, which diverges from
419 traditional classifications, allows for a deeper understanding of the pathophysiological variations
420 within endometriosis and highlights the necessity of tailored therapeutic approaches.

421 After deriving and characterizing the clusters in the non-genotyped PMBB, we used a k-
422 nearest neighbors' model to transfer the subtypes to the other four EHR-linked genetic datasets,
423 PMBB, eMERGE, AOU, and UKBB. We performed ancestry-stratified candidate gene testing for each
424 of the clusters using SAIGE and identified eight genome-wide significant signals. The genetic
425 analysis of these clusters yielded intriguing results. While 46% of previously known GWAS loci
426 were replicated in our study, significant differences in loci associations across the clusters were
427 observed. For instance, genes like *WNT4* and *GREB1* showed specific associations with the uterine
428 disorders and EHR asymptomatic clusters, suggesting that these genes might play distinct roles in
429 the pathogenesis of these phenotypic presentations of endometriosis. Conversely, the *BSN* gene,
430 although not statistically significant, demonstrated greater significance in the pain and pregnancy
431 complications clusters, indicating a possible link to neurovascular or inflammatory mechanisms
432 that could exacerbate these conditions.

433 Renalase (RNLS) is the protein associated with our only genome-wide significant
434 association from the positive control, *RNLS/10q23.31*. At the Bonferroni significance threshold, the
435 association with RNLS was significant for three out of five sub-phenotypes: pregnancy
436 complications, cardiometabolic comorbidities, and EHR-asymptomatic. It was the only significant
437 association with the cardiometabolic cluster. *RNLS* is highly expressed in the heart and contributes
438 to regulating blood pressure (43). In genetic association studies, *RNLS* has been previously
439 associated with type 1 diabetes (44) and smoking initiation (45). Smoking is a known risk factor of
440 endometriosis.

441 Cluster three, with high rates of pregnancy-related complications such as infertility and
442 high-risk pregnancy, was significantly associated with seven loci including *FSHB* ($P = 1.8 \times 10^{-4}$).
443 The *FSHB* gene codes for the beta-subunit of follicle-stimulating hormone (FSH). FSH is essential for
444 female fertility and has been shown to regulate myometrial contractile activity (46). *FSHB* was
445 significantly associated with the positive control as well, but not with any of the other clusters.

446 Cluster five, which was largely asymptomatic in the EHR, was the largest cluster. Over half
447 (56%) of UKBB endometriosis patients were assigned to this cluster. It is possible that those
448 assigned to this cluster from any dataset have symptoms that were not recorded in the structured
449 data which we had access to. Two well-known endometriosis loci from both of the last major
450 GWASs are *SYNE1* and *CDKN2B-AS1* (16,17), both of which were significantly associated with the
451 positive control and the EHR-asymptomatic cluster. Six loci were associated with this cluster and no
452 other phenotypes: *BSN*, *ID4*, *CD109*, *MLLT10*, *IGF1*, and *SKAP1*. *MLLT10* and *BSN* have been
453 previously associated with pain perception and maintenance (17). Serum levels of IGF-1 are
454 significantly elevated in women with endometriosis (47). Gene expression of *ID4* is down-regulated
455 in eutopic and ectopic endometrial tissue of women with endometriosis (48). *CD109I* and *SKAP1*
456 have been previously associated with endometrial cancers (49,50).

457

458 Subtyping complex diseases, like endometriosis, is crucial for advancing precision medicine.
459 The findings from our study underscore the utility of EHR as a rich resource for disease subtyping
460 and genetic research. The linkage of detailed clinical data with genetic information enables the
461 identification of phenotype-genotype correlations that are often diluted in broader GWAS analyses.
462 Furthermore, the use of spectral clustering helps elucidate the heterogeneity within endometriosis,
463 providing a framework for understanding the multifaceted nature of the disease and facilitating the
464 development of personalized medicine.

465 However, it is essential to acknowledge the limitations of our study. One significant
466 constraint was the sample size, which was particularly limited for some of the smaller clusters and
467 for individuals of non-European ancestry. This limitation could potentially introduce bias and affect
468 the generalizability of our findings. Additionally, our study relies on structured electronic health
469 data only, which may not capture the full clinical picture and could be subject to inaccuracies or
470 incomplete records. Lastly, this genetic association analyses in this study only focused on the
471 candidate genes that are previously known to be associated with endometriosis. This approach
472 might have restricted our ability to discover novel genetic loci potentially relevant to the specific
473 clusters identified. Despite these limitations, our study marks a meaningful advancement in
474 understanding the genetic factors that may contribute to the heterogeneity observed in
475 endometriosis. By focusing on genetic associations gleaned from electronic health records, we offer
476 a novel perspective that could be instrumental in future research and treatment approaches. To
477 expand upon the current findings, future research should aim to perform comprehensive GWAS
478 across the identified endometriosis subtypes. This will enable the detection of novel loci that could
479 be crucial for understanding the distinct mechanisms underlying each subtype. Additionally,
480 integrating multi-omics data (such as transcriptomic, proteomic, and metabolomic data) could
481 further refine the molecular signatures associated with each cluster, enhancing the biological
482 interpretability of the genetic associations. Another promising avenue is the longitudinal study of

483 these clusters to assess disease progression and treatment outcomes, which could inform more
484 effective, personalized therapeutic strategies.

485 In conclusion, our research highlights the importance of subtype-specific studies in
486 elucidating the genetic basis of endometriosis. By leveraging the capabilities of EHR-linked
487 biobanks and employing advanced clustering techniques, we pave the way for more targeted and
488 effective approaches to understanding and managing this complex disease.

489 Acknowledgements

490 Research reported in this publication was supported by the Eunice Kennedy Shriver National
491 Institute of Child Health and Human Development of the National Institutes of Health under award
492 number R01HD110567.

493
494 We acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient-
495 participants of Penn Medicine who consented to participate in this research program. We would
496 also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing
497 genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 and
498 supported by Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow
499 family, and the National Center for Advancing Translational Sciences of the National Institutes of
500 Health under CTSA award number UL1TR001878.

501
502 This phase of the eMERGE Network was initiated and funded by the NHGRI through the following
503 grants: U01HG008657 (Group Health Cooperative/University of Washington); U01HG008685
504 (Brigham and Women's Hospital); U01HG008672 (Vanderbilt University Medical Center);
505 U01HG008666 (Cincinnati Children's Hospital Medical Center); U01HG006379 (Mayo Clinic);
506 U01HG008679 (Geisinger Clinic); U01HG008680 (Columbia University Health Sciences);

507 U01HG008684 (Children's Hospital of Philadelphia); U01HG008673 (Northwestern University);
508 U01HG008701 (Vanderbilt University Medical Center serving as the Coordinating Center);
509 U01HG008676 (Partners Healthcare/Broad Institute); and U01HG008664 (Baylor College of
510 Medicine).

511
512 We gratefully acknowledge All of Us participants for their contributions, without whom this
513 research would not have been possible. We also thank the National Institutes of Health's All of Us
514 Research Program for making available the participant data examined in this study.

515
516 This research has been conducted using the UK Biobank Resource under Application Number
517 32133.

518 References

- 519 1. Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL. Economic burden of
520 endometriosis. *Fertil Steril*. 2006 Dec 1;86(6):1561-72.
- 521 2. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. *Fertil Steril*. 2012
522 Sep 1;98(3):511-9.
- 523 3. Greene R, Stratton P, Cleary SD, Ballweg ML, Sinai N. Diagnostic experience among 4,334
524 women reporting surgically diagnosed endometriosis. *Fertil Steril*. 2009 Jan;91(1):32-9.
- 525 4. As-Sanie S, Soliman AM, Evans K, Erpelding N, Lanier RK, Katz NP. Short-acting and Long-acting
526 Opioids Utilization among Women Diagnosed with Endometriosis in the United States: A
527 Population-based Claims Study. *J Minim Invasive Gynecol*. 2021 Feb 1;28(2):297-306.e2.
- 528 5. Soliman AM, Surrey E, Bonafede M, Nelson JK, Castelli-Haley J. Real-World Evaluation of Direct
529 and Indirect Economic Burden Among Endometriosis Patients in the United States. *Adv Ther*.
530 2018 Mar 1;35(3):408-23.
- 531 6. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical Treatment of Endometriosis: A 7-
532 Year Follow-up on the Requirement for Further Surgery. *Obstet Gynecol*. 2008
533 Jun;111(6):1285.
- 534 7. Singh SS, Suen MWH. Surgery for endometriosis: beyond medical therapies. *Fertil Steril*. 2017
535 Mar 1;107(3):549-54.

- 536 8. Ellis K, Munro D, Clarke J. Endometriosis Is Undervalued: A Call to Action. *Front Glob Womens*
537 *Health* [Internet]. 2022 [cited 2022 Dec 1];3. Available from:
538 <https://www.frontiersin.org/articles/10.3389/fgwh.2022.902371>
- 539 9. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of
540 endometriosis: costs and quality of life of women with endometriosis and treated in referral
541 centres. *Hum Reprod Oxf Engl*. 2012 May;27(5):1292–9.
- 542 10. Penrod N, Okeh C, Velez Edwards DR, Barnhart K, Senapati S, Verma SS. Leveraging electronic
543 health record data for endometriosis research. *Front Digit Health* [Internet]. 2023 Jun 5 [cited
544 2024 Apr 12];5. Available from: [https://www.frontiersin.org/journals/digital-](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fgth.2023.1150687/full)
545 [health/articles/10.3389/fgth.2023.1150687/full](https://www.frontiersin.org/journals/digital-health/articles/10.3389/fgth.2023.1150687/full)
- 546 11. Soliman AM, Fuldeore M, Snabes MC. Factors Associated with Time to Endometriosis Diagnosis
547 in the United States. *J Womens Health*. 2017 Jul;26(7):788–97.
- 548 12. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al. ESHRE guideline:
549 endometriosis†. *Hum Reprod Open*. 2022 Jan 1;2022(2):hoac009.
- 550 13. Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a
551 systematic quantitative review. *BJOG Int J Obstet Gynaecol*. 2004 Nov;111(11):1204–12.
- 552 14. Nisolle M, Painsaveine B, Bourdon A, Berlière M, Casanas-Roux F, Donnez J. Histologic study of
553 peritoneal endometriosis in infertile women. *Fertil Steril*. 1990 Jun;53(6):984–8.
- 554 15. Fauconnier A, Fritel X, Chapron C. [Endometriosis and pelvic pain: epidemiological evidence of
555 the relationship and implications]. *Gynecol Obstet Fertil*. 2009 Jan;37(1):57–69.
- 556 16. Sapkota Y, Steinhorsdottir V, Morris AP, Fassbender A, Rahmioglu N, De Vivo I, et al. Meta-
557 analysis identifies five novel loci associated with endometriosis highlighting key genes involved
558 in hormone metabolism. *Nat Commun*. 2017 May 24;8(1):15539.
- 559 17. Rahmioglu N, Mortlock S, Ghiasi M, Møller PL, Stefansdottir L, Galarneau G, et al. The genetic
560 basis of endometriosis and comorbidity with other pain and inflammatory conditions. *Nat*
561 *Genet*. 2023 Mar;55(3):423–36.
- 562 18. Saha R, Pettersson HJ, Svedberg P, Olovsson M, Bergqvist A, Marions L, et al. Heritability of
563 endometriosis. *Fertil Steril*. 2015 Oct 1;104(4):947–52.
- 564 19. Lee SH, Harold D, Nyholt DR, Goddard ME, Zondervan KT, Williams J, et al. Estimation and
565 partitioning of polygenic variation captured by common SNPs for Alzheimer’s disease, multiple
566 sclerosis and endometriosis. *Hum Mol Genet*. 2013 Feb 15;22(4):832–41.
- 567 20. Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with
568 chronic pelvic pain and endometriosis. *Hum Reprod Update*. 2014;20(5):737–47.
- 569 21. Nezhat C, Li A, Abed S, Balassiano E, Soliemannjad R, Nezhat A, et al. Strong Association
570 Between Endometriosis and Symptomatic Leiomyomas. *JSLs*. 2016;20(3):e2016.00053.

- 571 22. Verma A, Damrauer SM, Naseer N, Weaver J, Kripke CM, Guare L, et al. The Penn Medicine
572 BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision
573 Medicine in a Diverse Population. *J Pers Med*. 2022 Dec;12(12):1974.
- 574 23. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic
575 Medical Records and Genomics (eMERGE) Network: past, present, and future. *Genet Med Off J*
576 *Am Coll Med Genet*. 2013 Oct;15(10):761–71.
- 577 24. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated
578 genes and pathways across eMERGE Network | SpringerLink [Internet]. [cited 2023 Aug 14].
579 Available from: <https://link.springer.com/article/10.1186/s12916-019-1364-z>
- 580 25. Data Browser | All of Us Public Data Browser [Internet]. [cited 2024 Mar 30]. Available from:
581 <https://databrowser.researchallofus.org/>
- 582 26. Genomic data in the All of Us Research Program. *Nature*. 2024;627(8003):340–6.
- 583 27. The “All of Us” Research Program. *N Engl J Med*. 2019 Aug 15;381(7):668–76.
- 584 28. Sync For Science [Internet]. [cited 2024 Mar 30]. Available from: <https://syncfor.science/>
- 585 29. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource
586 with deep phenotyping and genomic data. *Nature*. 2018 Oct;562(7726):203–9.
- 587 30. Hallinan CM, Ward R, Hart GK, Sullivan C, Pratt N, Ng AP, et al. Seamless EMR data access:
588 Integrated governance, digital health and the OMOP-CDM. *BMJ Health Care Inform*. 2024 Feb
589 21;31(1):e100953.
- 590 31. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012 Nov
591 1;491(7422):56–65.
- 592 32. Jia H, Ding S, Xu X, Nie R. The latest research progress on spectral clustering. *Neural Comput*
593 *Appl*. 2014 Jun 1;24(7):1477–86.
- 594 33. Damle A, Minden V, Ying L. Simple, direct and efficient multi-way spectral clustering. *Inf*
595 *Inference J IMA*. 2019 Mar 15;8(1):181–203.
- 596 34. Khan K, Rehman SU, Aziz K, Fong S, Sarasvady S. DBSCAN: Past, present and future. In: *The Fifth*
597 *International Conference on the Applications of Digital Information and Web Technologies*
598 *(ICADIWT 2014)* [Internet]. 2014 [cited 2024 Mar 30]. p. 232–8. Available from:
599 <https://ieeexplore.ieee.org/abstract/document/6814687>
- 600 35. Algorithms for hierarchical clustering: an overview - Murtagh - 2012 - WIREs Data Mining and
601 Knowledge Discovery - Wiley Online Library [Internet]. [cited 2024 Mar 30]. Available from:
602 <https://wires.onlinelibrary.wiley.com/doi/full/10.1002/widm.53>
- 603 36. Kanungo T, Mount DM, Netanyahu NS, Piatko CD, Silverman R, Wu AY. An efficient k-means
604 clustering algorithm: analysis and implementation. *IEEE Trans Pattern Anal Mach Intell*. 2002
605 Jul;24(7):881–92.

- 606 37. Watts V. 9.5 Statistical Inference for Two Population Proportions. 2022 Sep 1 [cited 2024 Apr
607 16]; Available from: [https://ecampusontario.pressbooks.pub/introstats/chapter/9-5-
statistical-inference-for-two-population-proportions/](https://ecampusontario.pressbooks.pub/introstats/chapter/9-5-
608 statistical-inference-for-two-population-proportions/)
- 609 38. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to
610 the challenge of larger and richer datasets. *GigaScience*. 2015 Dec 1;4(1):s13742-015-0047-8.
- 611 39. Islam MJ, Wu QMJ, Ahmadi M, Sid-Ahmed MA. Investigating the Performance of Naive- Bayes
612 Classifiers and K- Nearest Neighbor Classifiers. In: 2007 International Conference on
613 Convergence Information Technology (ICCIT 2007) [Internet]. 2007 [cited 2024 Apr 16]. p.
614 1541–6. Available from: <https://ieeexplore.ieee.org/abstract/document/4420473>
- 615 40. Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling
616 for case-control imbalance and sample relatedness in large-scale genetic association studies.
617 *Nat Genet*. 2018 Sep;50(9):1335–41.
- 618 41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set
619 for Whole-Genome Association and Population-Based Linkage Analyses. *Am J Hum Genet*. 2007
620 Sep;81(3):559–75.
- 621 42. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and
622 random-effects models for meta-analysis. *Res Synth Methods*. 2010;1(2):97–111.
- 623 43. Heydarpour M, Parksook WW, Hopkins PN, Pojoga LH, Williams GH, Williams JS. A candidate
624 locus in the renalase gene and susceptibility to blood pressure responses to the dietary salt. *J
625 Hypertens*. 2023 May;41(5):723.
- 626 44. Onengut-Gumuscu S, Chen WM, Burren O, Cooper NJ, Quinlan AR, Mychaleckyj JC, et al. Fine
627 mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants
628 with lymphoid gene enhancers. *Nat Genet*. 2015 Apr;47(4):381–6.
- 629 45. Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene
630 discovery for tobacco and alcohol use. *Nature*. 2022 Dec;612(7941):720–4.
- 631 46. Stilley JAW, Segaloff DL. FSH Actions and Pregnancy: Looking Beyond Ovarian FSH Receptors.
632 *Endocrinology*. 2018 Dec 1;159(12):4033–42.
- 633 47. Heidari S, Kolahdouz-Mohammadi R, Khodaverdi S, Tajik N, Delbandi AA. Expression levels of
634 MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls.
635 *BMC Womens Health*. 2021 Dec 20;21(1):422.
- 636 48. Amirteimouri S, Ashini M, Ramazanali F, Aflatoonian R, Afsharian P, Shahhoseini M. Epigenetic
637 role of the nuclear factor NF-Y on ID gene family in endometrial tissues of women with
638 endometriosis: a case control study. *Reprod Biol Endocrinol*. 2019 Mar 15;17(1):32.
- 639 49. Al-kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alexiou A, Papadakis M, Saad HM, et al. The
640 possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review.
641 *Cancer Rep*. 2024;7(1):e1920.

642 50. Kho PF, Wang X, Cuéllar-Partida G, Dörk T, Goode EL, Lambrechts D, et al. Multi-tissue
643 transcriptome-wide association study identifies eight candidate genes and tissue-specific gene
644 expression underlying endometrial cancer susceptibility. *Commun Biol.* 2021 Oct 21;4(1):1–8.

645